Exchange: NASDAQ·Updated 07:30 PM EST

IFRX News

News
all
press releases
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers InflaRx (NASDAQ:IFRX) stock rose 12.7% to $1.32 during Friday's after-market session. The market value of their outstanding shares is at $182.6 million. Instinct Bio Technical Co (NASDAQ:BIOT) stock movedread more...
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers InflaRx (NASDAQ:IFRX) stock rose 12.7% to $1.32 during Friday's after-market session. The market value of their outstanding shares is at $182.6 million. Instinct Bio Technical Co (NASDAQ:BIOT) stock movedread more...
Benzinga
More News
InflaRx (IFRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Zacks
The heavy selling pressure might have exhausted for InflaRx (IFRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks
Certara (CERT) delivered earnings and revenue surprises of -20.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for some of medicine's most difficult-to-treat diseases. Among the most closely watched areas is the complement system, a network of proteins that can trigger severe tissue damage when overactivated. With growing interest in kidney disorders and autoimmune diseases, investors are increasingly rewarding companies developing targeted therapies capable of interrupting these pathways with greater precision and fewer side effects.Shares of InflaRx N.V. ...
AllPennyStocks.com
The immune system has become one of biotech's most important battlegrounds as drug developers race to target inflammatory pathways responsible for some of medicine's most difficult-to-treat diseases. Among the most closely watched areas is the complement system, a network of proteins that can trigger severe tissue damage when overactivated. With growing interest in kidney disorders and autoimmune diseases, investors are increasingly rewarding companies developing targeted therapies capable of interrupting these pathways with greater precision and fewer side effects.Shares of InflaRx N.V. ...
AllPennyStocks.com
InflaRx N.V. (NASDAQ:IFRX - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 1,809,027 shares, a decline of 26.2% from the March 31st total of 2,452,174 shares. Approximately 3.0% of the company's stock are short...
MarketBeat
InflaRx (NASDAQ:IFRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-inflarx-stock...
MarketBeat
Oppenheimer initiated coverage on InflaRx in a report on Friday. They set an "outperform" rating and a $5.00 price target on the stock...
MarketBeat

Advertisement|Remove ads.